Advanced Medical Institute Inc. (Pink Sheets:AVMD), a leading provider of treatment for erectile dysfunction (ED) and treatment for premature ejaculation (PE) in Australia will be among the eleven companies taking part in the EQUITIES Magazine Corporate Transatlantic Conference scheduled to take place at the major stock exchanges in New York, London and Milan September 15-20 it was announced today by Dr. Jacov Vaisman, founder, president, CEO and Chairman of the Board of Directors.
The EQUITIES Conference will begin in New York at The American Stock Exchange on September 15, continue on September 18 at the new London Stock Exchange and end at the Borso Milano in Milan on September 20. Mr. Richard Doyle will represent the Company at the conference.
"This is the third EQUITIES Conference we have taken part in and the first transatlantic conference for AVMD. We are committed to an ongoing program to keep our shareholders and potential shareholders informed," Vaisman said. "We believe these conferences are an excellent way to update the financial community on our continuing progress and also offer the opportunity to meet with major shareholders and other members of the financial community in New York and London," he added.
For additional information about AVMD please see the Company's website at http://www.avmd.com.au or contact Trudy Self at 909-336-5685.
About the Company
Advanced Medical Institute Inc., (Pink Sheets:AVMD), headquartered in Sydney, Australia, is a leading provider of treatment programs for erectile dysfunction and premature ejaculation. The Company operates 22 treatment clinics in Australia and New Zealand, a centralized call center in Australia, has more than 220 employees, including 51 medical personnel, and since its inception has provided treatment to more than 300,000 patients. AMI Australia and its predecessor company began treating ED and PE patients successfully 6 years prior to the launch of Viagra, in 1999, in Australia.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward- looking statements are based on current expectations or beliefs, including, but not limited to, statements concerning the company's operations and financial performance and condition. For this purpose, statements that are not statements of historical fact may be deemed to be forward-looking statements. The company cautions that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others, the impact of competitive products and pricing; changes in consumer preferences and tastes or perceptions of health-related issues; effectiveness of advertising or market-spending programs; changes in laws and regulations; fluctuations in costs of production, foreign exchange and interest rates; and other factors as those discussed in the Company's reports filed with the Securities and Exchange Commission from time to time.